Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients
The Pharmacogenomics Journal2012Vol. 13(6), pp. 484–489
Citations Over TimeTop 12% of 2012 papers
Abiy Habtewold, Wondwossen Amogne, Eyasu Makonnen, Getnet Yimer, Hanna Nylén, K. Riedel, Getachew Aderaye, Leif Bertilsson, Jürgen Burhenne, Ulf Diczfalusy, Eleni Aklillu
Related Papers
- → The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity(2003)591 cited
- → Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry(2019)63 cited
- → CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans(2011)49 cited
- → CYP2B6Variants and Plasma Efavirenz Concentrations during Antiretroviral Therapy in Port‐au‐Prince, Haiti(2009)39 cited
- → Influence of CYP2B6 Pharmacogenetics on Stereoselective Inhibition and Induction of Bupropion Metabolism by Efavirenz in Healthy Volunteers(2022)7 cited